Polytherics applies specific conjugation technologies for optimising pharmacokinetics and pharmacodynamics to a wide range of novel and established therapeutic proteins, including antibody fragments, enzymes, blood factors, cytokines, novel protein scaffolds, and peptides. They have also applied their technologies to produce better antibody drug conjugates (ADCs) using whole antibodies, novel antibody formats and antibody fragments and they have access, via their partners, to a range of cytotoxic drugs with different mechanisms of action.

In addition to in-house conjugation, Polytheric's scientists have expertise in designing and managing in vivo pharmacokinetic, pharmacodynamic and xenograft studies which can be set-up and managed on their behalf.

They collaborate with a wide range of organisations from virtual companies through to big pharma, including many of the world’s top companies, as well as academic research groups from across the globe.



BioFrontline managed a project with synthetic chemists, conjugation biologists, and chemical and bio analysts to set up a production platform for antibody drug conjugates (ADCs), so-called ‘magic bullets’, as new oncology treatments. After establishing a strategy and defining the milestones BioFrontline coordinated the project teams to ensure that targets were met, resulting in Polytherics’ first successful animal study of these newly developed biologics.

More information can be found at http://www.polytherics.com/

Polytherics is now part of Abzena